Jul 06, 2022 / 12:30PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to Sarepta Therapeutics' SRP-9001 New Clinical Data and Integrated Analysis Conference Call. (Operator Instructions) As a reminder, today's program is being recorded.
At this time, I'll turn the call over to Doug Ingram, President and Chief Executive Officer. Please go ahead.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you, Michelle, and thank you all for joining us today for a review of our most recent results regarding the functional benefits and safety of SRP-9001, our gene therapy.
After literally 1.5 decades of rational design, testing, optimization, brilliant preclinical evidence and then repeatedly confirming across multiple studies, SRP-9001 safety and efficacy profile, we, at Sarepta, have developed, as you can imagine, a significant conviction in the potential of SRP-9001 to change the trajectory of this disease, Duchenne. So you can also imagine how difficult it would be to exceed our expectations in the transformative potential of this
Sarepta Therapeutics Inc to Discuss New Clinical Data and Integrated Analysis Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers